EA201992825A1 - THREE COMPONENT COMBINED ANTIBODIES - Google Patents

THREE COMPONENT COMBINED ANTIBODIES

Info

Publication number
EA201992825A1
EA201992825A1 EA201992825A EA201992825A EA201992825A1 EA 201992825 A1 EA201992825 A1 EA 201992825A1 EA 201992825 A EA201992825 A EA 201992825A EA 201992825 A EA201992825 A EA 201992825A EA 201992825 A1 EA201992825 A1 EA 201992825A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
component combined
combined antibodies
component
control point
Prior art date
Application number
EA201992825A
Other languages
Russian (ru)
Inventor
Спенсер Лян
Лин Леун
Сара Вилан
Майа Коттури
Артур Махленкин
Эран Офир
Зоя Альтебер
Мейр Азулай
Катрин Логронио
Сандип КУМАР
Радика Десай
Кристофер Чан
Original Assignee
Компьюджен Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Компьюджен Лтд. filed Critical Компьюджен Лтд.
Priority claimed from PCT/IB2018/000696 external-priority patent/WO2018220446A1/en
Publication of EA201992825A1 publication Critical patent/EA201992825A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к трехкомпонентной комбинированной терапии с применением антител анти-TIGIT, антител анти-PVRIG и ингибиторов контрольных точек, включая антитела анти-PD-1 или анти-PD-L1.This invention relates to three-part combination therapy using anti-TIGIT antibodies, anti-PVRIG antibodies and control point inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.

EA201992825A 2018-01-16 2018-06-01 THREE COMPONENT COMBINED ANTIBODIES EA201992825A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862618005P 2018-01-16 2018-01-16
PCT/IB2018/000696 WO2018220446A1 (en) 2017-06-01 2018-06-01 Triple combination antibody therapies

Publications (1)

Publication Number Publication Date
EA201992825A1 true EA201992825A1 (en) 2020-04-15

Family

ID=70546484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992825A EA201992825A1 (en) 2018-01-16 2018-06-01 THREE COMPONENT COMBINED ANTIBODIES

Country Status (1)

Country Link
EA (1) EA201992825A1 (en)

Similar Documents

Publication Publication Date Title
MX2019014265A (en) Triple combination antibody therapies.
TR201901445T4 (en) Il2rbeta / common gamma chain antibodies.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
EA201890790A1 (en) CONNECTING PD-1 PROTEINS AND METHODS OF THEIR APPLICATION
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
EA202092825A1 (en) ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION
EA202092000A1 (en) EGFR DIMERIZATION INHIBITORS AND THEIR USE
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
BR112017023579A2 (en) combining a cd30xcd16 antibody with a pd-1 antagonist for therapy
BR112016027881A2 (en) pdl-1 and pd-1 antagonists for the treatment of hpv-negative cancers
PH12019500145A1 (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-á)
EA201990672A1 (en) ANTIBODIES SPECIFICALLY RELATING TO PD-1, AND THEIR FUNCTIONAL FRAGMENTS
EA201890578A1 (en) PREVENTION, TREATMENT AND REDUCTION (PERSISTENT) OF POST-TRAUMATIC HEADACHE
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA201991729A1 (en) ANTIBODIES TO TGF-BETA AND THEIR APPLICATION
BR112021012631A2 (en) Anti-ctla4 antibodies and methods of using them
MX2019010797A (en) Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer.
EA202190138A1 (en) ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE
EA201792561A1 (en) ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION
EA201991876A1 (en) ANTIBODIES AGAINST FACTOR D AND THEIR APPLICATION
NZ729395A (en) Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
EA201992318A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN
EA201892368A1 (en) ERBB INHIBITORS AND THEIR APPLICATION
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same